Login to Your Account

Amgen Drops GKA Partnership; Array Focusing on Other Drugs

By Catherine Shaffer
Staff Writer

Thursday, August 8, 2013
Amgen Inc. quietly backed out of its partnership with Array Biopharma Inc. for development of glucokinase activators (GKA), returning the program, including lead candidate ARRY-403, back to Array. The collaboration dates to 2009, when Amgen paid $60 million up front plus research funding for worldwide rights to Array's small-molecule GKA program.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription